Stem Cell Clinic

NBA Star John Salley Partners with Stem Cell Centers of Excellence … – Market Exclusive

By adminJune 30, 2017Stem Cell Clinic

WEST PALM BEACH, FL / ACCESSWIRE / June 29, 2017 / Steve Nudelberg, Principal Thinker of On the Ball Ventures, is pleased to announce the partnership between John Salley and Stem Cell Centers of Excellence.

On June 24, 2017, John Salley had his first stem cell procedure to harvest his own stem cells and create relief in his shoulders and knees. On the Ball, in keeping with our mantra to create ideas and opportunities to grow business, felt that John Salley would be a natural addition to enhance the national roll out of Stem Cell Centers of Excellence treatment clinics. As a spokesperson for the vegan lifestyle and long-time friend of On the Ball, John has a keen understanding of how the body functions and how stem cell treatment is a natural alternative for the athlete community. John is a perfect conduit, says Steve Nudelberg

John Salley, Entrepreneur, NBA Star, Actor, Philanthropist, and Vegan, has suffered years of agonizing pain after a lucrative career in the NBA. He was set to have surgery on his knees and shoulders but, in keeping with his vegan, clean philosophy, Salley partnered with Stem Cell Centers of Excellence to advocate for using your own bodys stem cells to heal itself. I am excited to be part of the future with the team at Stem Cell Centers of Excellence. Two things jump to mind after my recent treatment: one, I cant wait for my body to start healing itself and, two, I feel secure in knowing that my stem cells, which are not getting any younger, are now stored and will be ready should I need them for future use at any time, says John Salley.

Superstar athlete and wellness expert John Salley is the ideal individual to represent Stem Cell Centers of Excellence as we continue educating the public about the benefits of stem cells and the bodys ability to heal itself, said Mike Tomas, President and CEO of U.S. Stem Cell Inc. John has seen first-hand how injuries to athletes, and sports enthusiasts alike, can be devastating with long recovery times. Cutting-edge stem cell treatments for individuals with orthopedic as well as neurological conditions are an excellent option for these patients to improve their quality of life.

With a new clinic in Miami, FL and additional clinics opening soon around the country, Stem Cell COE provides comprehensive stem cell treatments using the U.S. Stem Cell Inc. (OTCQB: USRM) innovative technologies and the latest USSC regenerative medicine research. After treatment, the bodys own healing potential may naturally repair and regenerate damaged tissue. U.S. Stem Cells team of scientists have pioneered in-clinic regenerative medicine protocols and helped thousands of patients to naturally heal. The company is at the forefront of this innovative technology and will continue to create unique solutions for patients in need. For more information or to make an appointment, visit http://www.stemcellcoe.com.

On the Ball has been in business for over twenty-two years. Starting out as a sports marketing company to a traditional marketing agency to business development resource. Acclaimed for its strategic thinking and sales-focused abilities, On the Ball specializes in all things sales. By investing time and talent in emerging ideas, the agency can specifically help companies grow.

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic), includes the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection, and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as may, will, to, plan, expect, believe, anticipate, intend, could, would, estimate, or continue, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our managements beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled Risk Factors in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Contact:

Aziel Shea [emailprotected] (561) 596-9402

SOURCE: U.S. Stem Cell, Inc.

See more here:
NBA Star John Salley Partners with Stem Cell Centers of Excellence ... - Market Exclusive

Stem Cells Play a Role in Acute Myeloid Leukemia Relapse – Technology Networks

By adminJune 30, 2017Stem Cell Clinic

Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.

They have also identified two distinct stem-cell like populations from which relapse can arise in different patients in this aggressive cancer that they previously showed starts in blood stem cells in the bone marrow.

The findings provide significant insights into cell types fated to relapse and can help accelerate the quest for new, upfront therapies, says Dr. Dick, a Senior Scientist at Princess Margaret Cancer Centre, University Health Network, and Professor in the Department of Molecular Genetics, University of Toronto. He holds the Canada Research Chair in Stem Cell Biology and is Co-leader of the Acute Leukemia Translational Research Initiative at the Ontario Institute for Cancer Research. This study was primarily undertaken by post-doctoral fellow Dr. Liran Shlush and Scientific Associate Dr. Amanda Mitchell.

"For the first time, we have married together knowledge of stem cell biology and genetics areas that historically have often been operating as separate camps to identify mutations stem cells carry and how they are related to one another in AML," says Dr. Dick, who pioneered the cancer stem cell field by identifying leukemia stem cells in 1994.

A decade ago, he replicated the entire human leukemia disease process by introducing oncogenes into normal human blood cells, transplanting them into xenografts (special immune-deficient mice that accept human grafts) and watching leukemia develop a motherlode discovery that has guided leukemia research ever since.

The researchers set out to solve the mystery of AML relapse by analysing paired patient samples of blood taken at the initial clinic visit and blood taken post-treatment when disease recurred.

"First, we asked what are the similarities and differences between these samples. We carried out detailed genetic studies and used whole genome sequencing to look at every part of the DNA at diagnosis, and every part of the DNA at relapse," says Dr. Dick. "Next, we asked in which cells are genetic changes occurring."

The two-part approach netted a set of mutations seen only at relapse that enabled the team to sift and sort leukemic and normal stem cells using tools developed in the Dick lab a few years ago to zero in on specific cell types fated to relapse.

"This is a story that couldn't have happened five years ago, but with the evolution of deep sequencing, we were able to use the technology at just the right time and harness it with what we've been working on for decades," he says.

Today's findings augment recent research also published in Nature (Dec.7, 2016) detailing the team's development of a "stemness biomarker" a 17-gene signature derived from leukemia stem cells that can predict at diagnosis which AML patients will respond to standard treatment.

Dr. Dick says: "Our new findings add to that knowledge and we hope that we will soon have a new biomarker that will tell whether a patient will respond to standard chemotherapy, and then another to track patients in remission to identify those where treatment failed and the rare leukemia stem cells are coming back.

"These new kinds of biomarkers will lead to new kinds of clinical trials with targeted chemotherapy. Right now, everybody gets one size fits all because in AML we've never had any opportunity to identify patients upfront, only after they relapse. Now we have the first step to identify these patients at the outset and during remission."

The research was funded by the Ontario Institute for Cancer Research, the Cancer Stem Cell Consortium via Genome Canada and the Ontario Genomics Institute, the Canadian Institutes of Health Research, the Canadian Cancer Society, the Terry Fox Foundation, a Canada Research Chair and The Princess Margaret Cancer Foundation.

This article has been republished frommaterialsprovided byUHN. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Shlush, L. I., Mitchell, A., Heisler, L., Abelson, S., Ng, S. W., Trotman-Grant, A., . . . Dick, J. E. (2017). Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. doi:10.1038/nature22993

Continue reading here:
Stem Cells Play a Role in Acute Myeloid Leukemia Relapse - Technology Networks

Hurray for Gurdon and Yamanaka, Nobel Prize Winners for Pro-life Medicine – Gilmer Mirror

By adminJune 30, 2017Embryonic Stem Cells

The research studies carried out by John B. Gurdon (Anglo-Saxon) and Shinya Yamanaka (Japanese) were awarded the Nobel Prize in Medicine. These two scientists are considered of being the fathers of cellular reprogramming. They have achieved to create cells that behave identically to embryonic cells, however, without having to destroy human embryos. The Swiss Academy declared that both Gurdon and Yamanaka have revolutionized the current knowledge of how cells and organisms are developed, which has led to the perfection of the absurd methods of diagnosis and therapy.

Jhon Bertrand Gurdon, professor of the Zoology Department of the University of Cambridge, admitted of feeling extremely honored for such a spectacular privilege.

Moreover, Shinya Yamanaka discovered the so called induced pluripotent stem cells (iPS), which have the same proprieties of the embryonic ones and are able to turn into whatever other type of body cell. He asserted that he will continue to conduct research in order to contribute to society and medicine. For him that is a duty.

Yamanaka created four types of genes that supply cells with their pluripotentiality, in other words, the same capacity that embryonic stem cells have. If implanted in differentiated cells, for example of skin, they become pluripotent stem cells. The iPS supply a vast amount of plasticity just as embryonic stem cells do, however, without requiring the extermination or cloning of human embryos, since the initial cells can be obtained from the same patient. In this aspect, these cells have the same status as adult stem cells do, with the advantage of their versatility.

The dilema that has been stirred by the iPS is being resolved due to recent studies carried out by Leisuke Kaji (Universidad de Edimburgo) and Andreas Nagy (Samuel Lunenfeld Research Institute of Mount Sinai Hospital of Toronto).

The created iPS perennially retain their pluripotentiality. There is still the need of research to be conducted concerning the control of the difference between these cells in order for them to create the tissue that is necessary for each case. As Kaji affirms in The Guardian, it is a step towards the practical use of reprogrammed cells in the field of medicine, which could eventually lead to eliminating the need of counting on human embryos as the main source of stem cells.

The Episcopal Subcommittee for the Family and Defense of Life of the Episcopal Conference, beliefs that no Catholic could support practices such as abortion, euthanasia or the production, freezing and/or manipulation of human embryos.

Clement Ferrer

Independent Forum of Opinion

http://indeforum.wordpress.com/

See the article here:
Hurray for Gurdon and Yamanaka, Nobel Prize Winners for Pro-life Medicine - Gilmer Mirror

GEN Roundup: Top Trends in Tissue Engineering – Genetic Engineering & Biotechnology News

By adminJune 30, 2017Embryonic Stem Cells

References

1. F.T. Moutos et al., Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing, Proc. Natl. Acad. Sci. U.S.A. 113 (31) E4513E4522, doi: 10.1073/pnas.1601639113.

2. B. Zhang et al., Biodegradable scaffold with built-in vasculature for organ-on-a-chip engineering and direct surgical anastomosis, Nat. Materials 15, 669678 (2016), doi:10.1038/nmat4570.

3. S. Shukla et al., Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1, Nat. Methods 14(5), 531-538 (May 2017),doi: 10.1038/nmeth.4258. Epub Apr 10, 2017.

4. M.M. Pakulska, S. Miersch, and M.S. Shoichet, Designer protein delivery: from natural occurring to engineered affinity controlled release systems, Science 351(6279):aac4750, doi: 10.1126/science.aac4750.

5. M.M. Pakulska, C.H. Tator, and M.S. Shoichet, Local delivery of chondroitinase ABC with or without stromal cell-derived factor 1 promotes functional repair in the injured rat spinal cord, Biomaterials (accepted April 2017).

6. TissueGene, TissueGene to Highlight Invossa, the Worlds First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis, at JP Morgan Healthcare Conference, Press Release,accessed June 12, 2017.

7. O.J.L. Rackham et al., A predictive computational framework for direct reprogramming between human cell types, Nat. Genetics 48, 331335 (2016), doi:10.1038/ng.3487.

8. D.B. Kolesky et al., Three-dimensional bioprinting of thick vascularized tissue, Proc. Natl. Acad. Sci. U.S.A. 113 (12), 31793184, doi: 10.1073/pnas.1521342113.

9. M.M. Laronda et al., A Bioprosthetic Ovary Created Using 3D Printed Microporous Scaffolds Restores Ovarian Function in Sterilized Mice, Nat. Commun. 8, 15261 (May 16, 2017).

10. I. Sagi et al., Derivation and differentiation of haploid human embryonic stem cells, Nature 532, 107111 (April 7, 2016), doi:10.1038/nature17408.

Scientists manipulate ‘signaling’ molecules to control cell migration – Phys.Org

By adminJune 30, 2017Uncategorized

June 30, 2017 Researchers have found a way to tweak cells' movement patterns to resemble those of other cell types. Credit: Tim Phelps/Johns Hopkins University

Johns Hopkins researchers report they have uncovered a mechanism in amoebae that rapidly changes the way cells migrate by resetting their sensitivity to the naturally occurring internal signaling events that drive such movement. The finding, described in a report published online March 28 in Nature Cell Biology, demonstrates that the migratory behavior of cells may be less "hard-wired" than previously thought, the researchers say, and advances the future possibility of finding ways to manipulate and control some deadly forms of cell migration, including cancer metastasis.

"In different tissues inside the body, cells adopt different ways to migrate, based on their genetic profile and environment," says Yuchuan Miao, a graduate student at the Johns Hopkins University School of Medicine and lead author of the study. "This gives them better efficiency to perform specific tasks." For example, white blood cells rhythmically extend small protrusions that allow them to squeeze through blood vessels, whereas skin cells glide, like moving "fans," to close wounds.

On the other hand, Miao notes, uncontrolled cell migration contributes to diseases, including cancer and atherosclerosis, the two leading causes of death in the United States. The migration of tumor cells to distant sites in the body, or metastasis, is what kills most cancer patients, and defective white blood cell migration causes atherosclerosis and inflammatory diseases, such as arthritis, which affects 54 million Americans and costs more than $125 billion annually in medical expenditures and lost earnings.

Because cells migrate in different ways, many drugs already designed to prevent migration work only narrowly and are rarely more than mildly effective, fueling the search for new strategies to control migratory switches and treat migration-related diseases, according to senior author Peter Devreotes, Ph.D., a professor and director of the Department of Cell Biology at the Johns Hopkins University School of Medicine's Institute for Basic Biomedical Research.

"People have thought that cells are typed by the way they look and migrate; our work shows that we can change the cell's migrating mode within minutes," adds Devreotes.

For the new study, Devreotes and his team focused on how chemical signaling molecules activate the motility machinery to generate protrusions, cellular "feet" that are a first step in migration. To do this, they engineered a strain of Dictyostelium discoideum, an amoeba that can move itself around in a manner similar to white blood cells. The engineered amoebae responded to the chemical rapamycin by rapidly moving the enzyme Inp54p to the cell surface, where it disrupted the signaling network. The cells also contained fluorescent proteins, or "markers," that lit up and showed researchers when and where signaling molecules were at work.

Experiments showed that the engineered cells changed their migration behavior within minutes of Inp54p recruitment. Some cells, which the researchers termed "oscillators," first extended protrusions all around the cell margins and then suddenly pulled them back again, moving in short spurts before repeating the cycle. Fluorescent markers showed that these cycles corresponded to alternating periods of total activation and inactivation, in contrast to the small bursts of activity seen in normal cells.

The video will load shortly

Other cells began to glide as "fans," with a broad zone of protrusions marked by persistent signaling activity.

Devreotes describes the signaling behavior at the cell surface as a series of waves of activated signaling molecules that switch on the cellular motility machinery as they spread. In their normal state, cells spontaneously initiated signaling events to form short-lived waves that made small protrusions.

In contrast, oscillators had faster signaling waves that reached the entire cell boundary to generate protrusions before dying out. Fans also showed expanded waves that continually activated the cell front without ever reaching the cell rear, resulting in wide, persistent protrusions.

The scientists say their experiments show that the cell movement changes they saw resulted from lowering the threshold level of signaling activity required to form a wave. That is, cells with a lower threshold are more likely to generate waves and, once initiated, the activation signals spread farther with each step.

Devreotes says the team's experimental results offer what appears to be the first direct evidence that waves of signaling molecules drive migratory behavior. Previously, his laboratory showed a link between signaling and migration, but had not specifically examined waves.

In further experiments, Devreotes and his team found that they could recruit different proteins to shift cell motility, suggesting, he says, that altering threshold is a general cell property that can change behaviorno matter how cells migrate. His team was also able to restore normal motility to fans and oscillators by blocking various signaling activities, suggesting new targets for drugs that could be designed to control migration.

Devreotes cautions that what happens in an amoeba may not have an exact counterpart in a human cell, but studies in his lab suggest that something like the wave-signaling mechanism they uncovered operates in human cells as well.

The bottom line, says Miao, is that "we now know we can change signaling wave behavior to control the types of protrusions cells make. When cells have different protrusions, they have different migratory modes. When we come to understand the essential differences between cells' migratory modes, we should have better ways to control them during disease conditions."

Explore further: How cells communicate to move together as a group

More information: Yuchuan Miao et al. Altering the threshold of an excitable signal transduction network changes cell migratory modes, Nature Cell Biology (2017). DOI: 10.1038/ncb3495

When an individual cell needs to move somewhere, it manages just fine on its own. It extends protrusions from its leading edge and retracts the trailing edge to scoot itself along, without having to worry about what the other ...

Cell migration is important for development and physiology of multicellular organisms. During embryonic development individual cells and cell clusters can move over relatively long distances, and cell migration is also essential ...

When Greek mythology and cell biology meet, you get the protein Callipygian, recently discovered and named by researchers at The Johns Hopkins University for its role in determining which area of a cell becomes the back as ...

(Medical Xpress) -- Discoveries by a Yale-led team of scientists could lead the way for development of new therapies for treating fibrosis and tumor metastasis. The researchers have both uncovered a signaling pathway that ...

Living cells respond to biochemical signals by moving toward those at higher concentration, a process carefully mapped out by biologists over the past several decades. But cells also move in response to mechanical forces, ...

This heart-shaped image shows two mouse skin cancer cells connected to each other with actin, a protein that is part of the cellular skeleton. Researchers use mouse cells like these to tease out the molecular methods that ...

Nature makes the vibrant pigments manufacturers want for foods and cosmetics, but getting them from plants to the products we buy is so difficult that many manufacturers rely on artificial colors. Now, researchers at Rensselaer ...

For centuries evolutionary biologists have been considering a difficult question: why do some animals 'choose' not to have children and instead help others rear their young? Researchers from Royal Holloway, University of ...

(Phys.org)A team of researchers at Purdue University in the U.S. and the University of Amsterdam and Universit catholique de Louvain in the Netherlands has isolated the gene responsible for producing a protein that aids ...

If cellular identity is to be maintained, it is important that actively transcribed chromatin stretches remain in a loose configuration as long as these genes are needed. Marc Bhler and his group have uncovered a novel ...

Photosynthesis is one of the most complicated and important processesresponsible for kick-starting Earth's food chain. While we have modeled its more-than-100 major steps, scientists are still discovering the purpose of ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See original here:
Scientists manipulate 'signaling' molecules to control cell migration - Phys.Org

Sartorius and Science to award a prize for regenerative medicine and cell therapy – EPM Magazine

By adminJune 30, 2017Uncategorized

The Sartorius and Science Prize for Regenerative Medicine & Cell Therapy is focused towards scientists advancing research (basic or translational) within the relevant fields, with the winner receiving $25,000 in prize money and being published inScience magazine.

Scientists who have gained a PhD or an MD during the past decade are invited to submit an essay on regenerative medicine, cell therapy, gene therapy or immunotherapy, as well as on materials or tissue engineering. The essays should be 1,000 words in length and should describe the applicants research and implications for regenerative medicine and cell immunotherapy, as well as include supporting documents.

In addition to the cash prize and publication in Science, the winner will receive a Sartorius product package for free. Furthermore, up to three runner-up essays will be published in Science Online and the writers of the runner-up essays will also receive a cash prize of $5,000.

This area [regenerative medicine and cell therapy] will play a major role in the future, said Gerry MacKay, member of the Sartorius Group executive committee and executive vice president of marketing, sales and services for Sartorius Lab Products & Services Division. Sartorius innovative bioanalytical tools help scientists answer fundamental and complex biological questions. We are excited to enable medical progress in these fields, both with our technologies and this award. The prize will be conferred as a token of appreciation to scientist.

Science is delighted to join Sartorius in awarding a prize in the exciting area of regenerative medicine and cell therapy, added Valda J. Vinson, deputy editor research of Science. We look forward to promoting basic or translational research in fields ranging from gene therapy to materials engineering, which has the potential to improve human health.

Applications will be accepted until 1 October and the awards ceremony will be held in 2018 in Goettingen, Germany.

Link:
Sartorius and Science to award a prize for regenerative medicine and cell therapy - EPM Magazine

Mayo-Connected Regenerative Medicine Startup Inks Downtown Rochester Lease – Twin Cities Business Magazine

By adminJune 30, 2017Uncategorized

A regenerative medicine startup led by a Mayo Clinic cardiologist is setting up shop in a downtown Rochesters Minnesota BioBusiness Center, according to newly filed city documents. The filing indicated Rion LLC, a Minnesota company registered to Dr. Atta Behfar of the Mayo Clinic Center for Regenerative Medicine, has signed a three-year lease for just over 2,000 square feet at the city-owned BioBusiness Center. The lease begins July 1. The nine-story BioBusiness Center opened in downtown Rochester in 2007 as a center for innovation in biotechnology, promoting the linkages between the researchers and practitioners at Mayo Clinic; instructors and students at the University of Minnesota Rochester, and the biotechnology business community. It houses the Mayo Clinic Business Accelerator among other tenants. Behfar is an assistant medical professor and leads a laboratory at Mayo concentrating on applying regenerative medicine the practice of using stem cells to regenerate damaged or missing tissue to prevent and cure chronic heart conditions. Specifically, his group focuses on development and use of both stem cells and protein-based therapies to reverse injury caused by lack of blood flow to the heart. The business direction of Rion, meanwhile, appears to be specifically geared toward a cutting-edge development in the field of regenerative medicine the use of extracellular vesicles (EVs) in speeding and directing the growth of regenerating tissues in the heart and elsewhere in the body. EVs, long brushed off by researchers as mere debris in the bloodstream, are membrane-enclosed spheres that break off from the surfaces of nearly all living cells when disturbed. They transport lipids, proteins and nucleic acids, and have now been found to be important players in cell-to-cell communication, influencing the behavior and even the identity of cells. Their emerging role in regenerative medicine could potentially be huge. For instance, by bioengineering them to transport protein payloads from stem cells, they can be used to signal the bodys own cells to regenerate tissue instead of transplanting the stem cells themselves, thus eliminating the chance of host immune system rejection. A patent application filed last year by Rion, Behfar, Mayo Center for Regenerative Medicine Director Dr. Andre Terzic and two other local inventors is aimed at adapting the healing properties of a specific type of EV into a unique kind of product that could have wide applications. It focuses on EVs derived from blood platelets, which are well known to stop bleeding, promote the growth of new tissues and blood vessels, relieve inflammation and provide a host of other benefits. The patent describes a system of encapsulating platelet EVs derived from human or animal blood into a platelet honey and delivering it to target areas of the body, such as damaged tissues or organs. Its purported effect is to regenerate, repair and restore damaged tissue, with possible uses including treating heart disease; healing damaged bones or joints; wound treatment; and cosmetic skin applications. A brief business description provided by Rion to Rochester city officials stated the company is focused on the delivery of cutting edge regenerative technologies to patients at low cost and in off-the-shelf fashion. Building on initial research at Mayo Clinic, Rion LLC aims to develop and bring to practice products in the space of wound healing, orthopedics and cardiac disease. The statement also added the company is an enthusiastic backer of Rochesters efforts to develop a local biotech business cluster, and is seeking to participate in the realization of the Destination Medical Center initiative.

Follow this link:
Mayo-Connected Regenerative Medicine Startup Inks Downtown Rochester Lease - Twin Cities Business Magazine

7th International Conference and Exhibition on Cell and Gene Therapy – Technology Networks

By adminJune 30, 2017Uncategorized

Conference Series LLC welcomes you to attend the 7th International Conference and Exhibition on Cell & Gene Therapy during March 15-17, 2018 at London, UK. We cordially invite all the participants who are interested in sharing their knowledge and research in the arena of Cell & Gene Therapy.

Cell and Gene Therapy Conference is to ameliorate the knowledge, awareness, and education on cell and gene therapy leading to the discovery of genetic and cellular therapies which aid to alleviate the human disease as it is the most significant emerging technology in the eyes of Medical, Biotechnology, Pharmaceuticals and Academia. Cell and Gene Therapy Conference 2018 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists.

Cell Therapy Conferences will provide a perfect platform to all the Doctors, Researchers Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere.

Gene Therapy Conferences strategic astuteness is to be an event for bringing together Scientists, Physicians, International mix of leading Universities, Cell Gene Therapy Institutions to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

This three-day Gene Therapy Event will address key issues concerning cell and gene therapy in the broader context of cellular and genetic disorder. Organized around daily themes, the Conference focuses on moving from present knowledge to future solutions

For more details: http://cellgenetherapy.conferenceseries.com/

Contact:

Angelica Kenova

Email: celltherapy@conferenceseries.net

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Continued here:
7th International Conference and Exhibition on Cell and Gene Therapy - Technology Networks

AML: Cellectis testing allogenic CAR-T cell therapy – European Biotechnology

By adminJune 30, 2017Uncategorized

Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.

The company said it enrolled the first patient with acute myeloid leukaemia (AML) to be treated with UCART123 at Weill at Cornell Medicine, New York Presbyterian Hospital. UCART123 is a TALEN-genome edited chimeric T cell receptor targeting the CD123/IL3R antigen on the surface of blasts and dendric cells, which is administered on allogeneic donor T cells. The team of Gail J. Roboz will investigate the safety and will collect first indications for efficacy of UCART123 in patients with AML. The Phase I trial is part of a strategic translational research alliance that was formed between Cellectis and Weill Cornell Medicine in 2015.

While Novartis AG and Kite Pharma are leading the CAR-T cell therapy development in AML, Cellectis hopes to overtake its competitors. It has the only approach that works with allogenic CAR-engineered T cells that could be centrally pre-manufactured in contrast to the autologous patient T cells. Those need to be isolated, engineered and expanded during the at least 14 day hospital stay of the patients to be treated making the procedure costly, lengthy and laborious. On the other hand, Cellectis therapy does not target the CD19 T cell antigen but CD123//IL3R giving the company another unique selling point.

Cellectis has used TALEN technology to block expression of the TCRa constant (TRAC) gene though blocking expression of the natural TCR. According to Andr Choulika, Cellectis CEO, TALEN technology shows less off-target effects compared to CRISPR/Cas9 genome editing. Following apheresis, donor T cells are engineered to express an anti-CD123 CAR (CD123 scFv-41BB-CD3z) and an RQR8 depletion ligand that confers susceptibility to rituximab. Theoretically, specifity of of UCART123 therapy might be higher in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) than in patients with AML as CD123 expression is 10fold higher in the precursors of plasmacytoid dendritic cells than in blast occurring in the course of AML.

Cellectis also announced two new entries to ists Board of Directors. Ex-Novartis pharma division head Rainer Boehm will lead commercialisation of Cellectis lead candidate. Ex Novartis Oncology President and Incyte Corp CEO Herv Hoppenot will lead clinical development.

View original post here:
AML: Cellectis testing allogenic CAR-T cell therapy - European Biotechnology

Stem-cell treatment arrives in Kamloops – Merritt Herald

By adminJune 30, 2017Stem Cell Treatment

Photo courtesy of Kamloops This Week.

By: Jessica Wallace (Kamloops This Week)

Gail Walsh didnt want to spend the rest of her days waiting.

The 72-year-old retired Peachland woman said she needed surgical procedures on both knees, hip, neck and back, but didnt want to sit on the waiting list. Instead, she researched alternatives and learned about a doctor in Kelowna offering private stem-cell treatment.

The retired teachers aid committed $6,500 with the hopes of checking some items off her list of procedures.

I thought, I can just see the rest of my days, waiting for surgery after surgery, then recuperating in between, Walsh told KTW. It just seemed to me it was worth the money to try.

Helping people on wait lists is among reasons why a longtime Kamloops neurosurgeon recently began offering stem-cell treatment, despite the fact the procedure is not approved by Health Canada.

The expense [of stem-cell treatment], itll never be offered in the public system, so Canada will be behind the rest of the world, Dr. Richard Brownlee told KTW.Lots of people will do medical tourism, theyll go to Mexico or the States or Germany or whatever to get treatment thats not available here. Wait lists are the other thing.People wait for a year to get a MRI, so if they dont have to wait, they can come in and get one in less than a week or two.

The Welcome Back Centre, a private pain-management clinic on Columbia Street, began offering stem-cell treatment three months ago.

Stem cells are prevalent in humans and can be extracted to help treat degenerative, inflammatory or autoimmune conditions, Brownlee said.

Under the right conditions, stem cells can adapt into other cells. Someone with arthritis may have stem cells injected into a joint to create new cartilage, while athletes may treat soft tissue after a muscle tear, he said.

Brownlee noted the medicine is evolving, even being used to slow down symptoms of but not cure amyotrophic lateral sclerosis (ALS/Lou Gehrigs Disease.)

Stem cells are what do the repairing, Brownlee said. So, if youre putting a big number of those locally at the site of where the injury is, it just encourages healing.

Controversy has surrounded embryonic stem-cell harvest from fetuses. Brownlee said it is both unethical and risky, being that young cells have the potential to change into anything, including cancer.

Much like organ transplant, there is also the risk of the body rejecting them. Brownlees office extracts stem cells from the adults who are receiving them.

If youre taking it directly from the person and processing it and putting it right back in, theres no issues with it, he said.

Brownlee said stem-cell treatment is ideal for people who either havent healed adequately or who have developed degenerative changes over time. Ranging from $5,000 to $10,000 per treatment, it is often sought as a last resort.

The centre has treated about a half-dozen knees and hips and is expanding into other treatments.

Nothing has 100 per cent effectiveness, but most of the conditions, about 85 per cent of people get benefit, Brownlee said.

In offering the first treatment of its kind in the city, Brownlee is educating the public and keeping up with new developments. He just got back from a conference in Beverly Hills through the Cell Surgical Network and said he is looking at joining the group to gain access to data from more than 7,000 cases.

Its just new and different and its something that will probably never be offered through the public system, he said.

As for Walsh, seven weeks after her first treatment, she said its too early to determine if the procedure was successful. Relief could take up to nine months.

All I know is so far, theres nothing harmful done, she said.

Future of stem cells

While Dr. Richard Brownlee said stem-cell treatment will likely never be offered publicly, Prime Minister Justin Trudeau last year announced $20 million in funding to the Centre for Commercialization of Regenerative Medicine to help establish a stem-cell therapy development facility in Toronto.

Regenerative medicine is the future and not only is it the future, its a branch of medicine that Canada and the province of Ontario are actually quite good at, Trudeau was quoted at the time in a story in the Globe and Mail about the announcement.

The medical advances and innovations happening right here in Toronto are world class.

Common applications:

Knees: partial to complete ligament tears, osteoarthritis, partial to complete meniscal tears, augmented ACL or PCL reconstruction;

Shoulder: partial to complete rotator cuff tears, labral tears, osteoarthritis;

Foot and ankle: tendon inflammation, osteoarthritis, patron to complete Achilles tendon tear;

Elbow, wrist and hand: partial to complete ligament tears, epicondylitis, osteoarthritis;

Spine: discogenic back pain, facet arthritis, degenerative disc disease;

Hip: osteoarthritis, labral tears, articular cartilage injuries, avascular necrosis.

Did you know?

Stem cells can be injected locally or delivered intravenously.

Gordie Howe underwent stem-cell therapy after having a stroke and responded well. His family said it helped him walk again, improved his speech and helped him gain weight.

Fat contains 100 to 1,000 times more stem cells than bone marrow.

Excerpt from:
Stem-cell treatment arrives in Kamloops - Merritt Herald